MedPath

Choriogonadotropin alfa

Generic Name
Choriogonadotropin alfa
Brand Names
Ovidrel, Ovitrelle, Pregnyl
Drug Type
Biotech
CAS Number
177073-44-8
Unique Ingredient Identifier
6413W06WR3
Background

Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.

Indication

For the treatment of female infertility

Associated Conditions
Secondary Hypogonadotrophic hypogonadism
Associated Therapies
Assisted Reproductive Technology therapy, Ovulation induction therapy

Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET

First Posted Date
2017-03-06
Last Posted Date
2017-03-06
Lead Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Target Recruit Count
252
Registration Number
NCT03071172
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China

🇨🇳

Peking University Third Hospital, Beijing, China

🇨🇳

The first Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

and more 4 locations

Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study

Phase 4
Conditions
Luteal Support
Embryo Transfer
Interventions
First Posted Date
2016-07-07
Last Posted Date
2016-12-13
Lead Sponsor
Sheba Medical Center
Target Recruit Count
62
Registration Number
NCT02825290
Locations
🇮🇱

Sheba medical center, Ramat Gan, Israel

Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.

Phase 3
Completed
Conditions
Infertility
Interventions
First Posted Date
2014-04-21
Last Posted Date
2017-06-12
Lead Sponsor
Instituto de Investigacion Sanitaria La Fe
Target Recruit Count
234
Registration Number
NCT02118051
Locations
🇪🇸

Human Reproduction Unit of the La Fe University and Politechnic Hospital, Valencia, Spain

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Phase 3
Completed
Conditions
Oligo-ovulation
Anovulation
Polycystic Ovarian Syndrome
Hypothalamic-pituitary Dysfunction
Interventions
Drug: urinary hCG (u-hCG)
First Posted Date
2012-07-31
Last Posted Date
2016-01-07
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
81
Registration Number
NCT01653743
Locations
🇯🇵

Bashamichi Ladies Clinic, Kanagawa, Japan

🇯🇵

Hanabusa Women's Central Fertility Clinic, Hyogo, Japan

🇯🇵

Sophia Ladies Clinic, Kanagawa, Japan

and more 3 locations

EXpression PRofile Endometrium Samples Study

Phase 4
Terminated
Conditions
In Vitro Fertilization
Interventions
Drug: Gonal -f® [r-hFSH]
Drug: Gonadotropin-releasing hormone (GnRH) Agonist
Drug: Gonadotropin-releasing hormone (GnRH) Antagonist
First Posted Date
2010-09-28
Last Posted Date
2013-12-27
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
27
Registration Number
NCT01210144
Locations
🇫🇷

Research Site, Paris, France

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Not Applicable
Conditions
Infertility
Interventions
First Posted Date
2010-09-20
Last Posted Date
2011-03-02
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
100
Registration Number
NCT01205009
Locations
🇮🇱

Hadassah Medical Center, Jerusalem, Israel

© Copyright 2025. All Rights Reserved by MedPath